Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02700919
Recruitment Status : Completed
First Posted : March 7, 2016
Results First Posted : November 30, 2020
Last Update Posted : November 30, 2020
Sponsor:
Information provided by (Responsible Party):
Mereo BioPharma

Brief Summary:
The purpose of this study is to compare the efficacy and safety of BCT197 when added on to standard of care in adult subjects with acute respiratory exacerbations of chronic obstructive pulmonary disease requiring hospitalization. Additionally, the study will characterize the pharmacokinetics of BCT197 in adults with COPD. The total duration of the study will be 26 weeks. Subjects will receive study treatment administration over a period of 5 days after randomization. It is expected that approximately 255 subjects will complete the study and follow-up.

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Drug: BCT197 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 282 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults
Actual Study Start Date : August 1, 2016
Actual Primary Completion Date : November 8, 2017
Actual Study Completion Date : November 28, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
Experimental: Regimen 1
Drug: BCT197 Dose 1, Day 1 to Day 5
Drug: BCT197
Capsules will be taken orally with fluids over a 5 day period after randomization

Experimental: Regimen 2
Drug: BCT197 Dose 2, Day 1 to Day 5
Drug: BCT197
Capsules will be taken orally with fluids over a 5 day period after randomization

Placebo Comparator: Regimen 3
Placebo Day 1 to Day 5
Drug: Placebo
Capsules will be taken orally with fluids over a 5 day period after randomization




Primary Outcome Measures :
  1. Change From Baseline in FEV1 to Day 7 - ITT Population [ Time Frame: Days 1 to 7 ]
    FEV1 data were recorded daily from Days 1 to 7 of the study using a computer-operated spirometer. Analysis was based on a linear Mixed Model for Repeated Measures (MMRM) with Change from Baseline in parameter as outcome; including treatment, visit, treatment by visit interaction, severity of airflow limitation at Baseline, blood eosinophils (%) at Baseline, time from start of current chronic obstructive pulmonary disease (COPD) exacerbation to first study treatment dosing, presence of cardiovascular comorbidities at Screening and COPD exacerbation treatment at Screening as fixed effects, and Baseline value and Baseline by visit interaction as covariates. Baseline was defined as the last non-missing value collected before the first study treatment administration, including unscheduled assessments. Results were presented with adjusted mean (95% confidence interval).


Secondary Outcome Measures :
  1. Change From Baseline in FEV1 on Days 3, 10, and 14 - ITT Population [ Time Frame: Days 3, 10, and 14 ]
    FEV1 data were recorded daily from Days 1 to 7, and Days 10 and 14 of the study using a computer-operated spirometer. Analysis was based on a linear MMRM with Change from Baseline in parameter as outcome; including treatment, visit, treatment by visit interaction, severity of airflow limitation at Baseline, blood eosinophils (%) at Baseline, time from start of current COPD exacerbation to first study treatment dosing, presence of cardiovascular comorbidities at Screening and COPD exacerbation treatment at Screening as fixed effects, and Baseline value and Baseline by visit interaction as covariates. Baseline was defined as the last non-missing value collected before the first study treatment administration, including unscheduled assessments.

  2. Normalization Evaluation of FEV1 Over Time (Days 1 to 7, Days 10 and 14, and Weeks 8, 12 and 26) Compared With the Most Recent Test Performed Within the Last 12 Months Outside an Exacerbation - ITT Population [ Time Frame: Baseline, Days 1 to 7, Days 10 and 14, Week 8, Week 12 and Week 26 ]
    FEV1 data were recorded daily from Days 1 to 7 and on Days 10 and 14 and Weeks 8, 12, and 26 of the study using a computer-operated spirometer. FEV1 normalization was achieved if FEV1 returned to a value ≥ 89% of the most recent FEV1 value measured within the last 12 months outside an exacerbation (pre-study FEV1 value). Baseline was defined as the last non-missing value collected before the first study treatment administration, including unscheduled assessments. Percentages (%) were based on number of non-missing values as denominator.

  3. Normalization Evaluation of FEV1/FVC Over Time (Days 1 to 7, Days 10 and 14, and Weeks 8, 12 and 26) Compared With the Most Recent Test Performed Within the Last 12 Months Outside an Exacerbation - ITT Population [ Time Frame: Baseline to Week 26 ]
    FEV1 and FVC were recorded daily from Days 1 to 7 and on Days 10 and 14 and Weeks 8, 12, and 26 of the study using a computer-operated spirometer. FEV1/FVC normalization was achieved if FEV1/FVC returned to a value ≥ 89% of the most recent FEV1/FVC value measured within the last 12 months outside an exacerbation (pre-study FEV1/FVC value). Baseline was defined as the last non-missing value collected before the first study treatment administration, including unscheduled assessments.

  4. Time to Improvement of 100 mL in FEV1 Over Time - ITT Population [ Time Frame: Baseline to Week 26 ]
    Time to improvement of 100 mL in FEV1 was defined as time (in days) from initiation of study treatment until the change in FEV1 was ≥ +100 mL.

  5. Area Under the Curve (AUC) of FEV1 Over Time - ITT Population [ Time Frame: Day 1 to Day 14 ]
    AUC was calculated according to the trapezoidal rule. The trapezoidal rule is a numerical method to be used to approximate the integral or the area under a curve. Using trapezoidal rule to approximate the area under a curve first involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when the upper end is replaced by a chord. The sum of these approximations gives the final numerical result of the AUC.

  6. Normalization of Respiratory Rate (RR) Over Time During Acute Exacerbation Phase - ITT Population [ Time Frame: Day 1 to Day 14 ]
    RR was normalized when it returned to a baseline plateau level achieved after the acute COPD exacerbation during the Stabilization Phase. Baseline was defined as the last non-missing value collected before the first study treatment administration, including unscheduled assessments.

  7. Change From Baseline in RR on Days 3, 7, 10 and 14 - ITT Population [ Time Frame: Days 1 to 14 ]
    RR (breaths/min) was recorded over time during the acute exacerbation phase.

  8. Time to Improvement Based on the EXAcerbations of Chronic Pulmonary Disease Tool-Patient Reported Outcome (EXACT-PRO) Total Score During the Acute Exacerbation Phase - ITT Population [ Time Frame: Days 1 to 29 ]
    Improvement based on EXACT-PRO total score is defined as a decrease in the Rolling Average EXACT score ≥ 9 points from the previous day's maximum observed value during an event. The EXACT is a 14-item patient reported outcome (PRO) daily diary used to quantify and measure exacerbations of COPD. The health status of the participant is correlated to the global score, meaning a higher score corresponds to a more severe health status of the participant. An EXACT Total score is computed for each day of diary collection. The EXACT Total score is based on a logit scoring system with conversion to a 0 to 100 scale for ease of interpretation and use. The total score was used in the determination of exacerbation frequency, severity and duration of exacerbation. Specifically, changes in the total score were used to define onset and recovery from an exacerbation event and the magnitude of that event.

  9. Time to Recovery Based on EXACT-PRO Total Score During the Acute Exacerbation Phase - ITT Population [ Time Frame: Days 1 to 29 ]
    Recovery based on EXACT-PRO total score was defined as the first day in which a participant experiences a persistent, sustained improvement in their condition over the observed period (Day 1 to Day 29). Improvement had to be present for 7 consecutive days. The first day of the 7-day period was designated as the first day of Recovery. An EXACT total score was computed for each day of diary collection.

  10. Standardized AUC of EXACT-PRO Rolling Average Over Time During Acute Exacerbation Phase - ITT Population [ Time Frame: Days 1 to 29 ]
    The standardized AUC of the EXACT-PRO were calculated from Day (a) to Day (b) using the trapezoidal rule.

  11. Standardized AUC of EXACT-PRO (Breathlessness) Rolling Average Over Time During Acute Exacerbation Phase - ITT Population [ Time Frame: Days 1 to 29 ]
    Information regarding the participant's condition can be obtained through 3 domain scores embedded within the EXACT measure: Breathlessness, Cough & Sputum, and Chest Symptoms. These scores also range from 0 to 100 with higher scores indicating more severe symptoms.The standardized AUC of the EXACT-PRO were calculated from Day (a) to Day (b) using the trapezoidal rule.

  12. Rate of Positively Adjudicated Moderate/Severe COPD Exacerbations - ITT Population [ Time Frame: Day 1 to End of Study (Day 180) ]
    Follow-up time per participant (years) was defined as (date of last contact - date of first study drug administration + 1)/ 365.25. Total follow-up time (years) = sum of individual participant follow-up times. Rate was calculated as total number of positively adjudicated exacerbations divided by the total follow-up time in years of the treatment group.

  13. Number of COPD-Related Deaths During the Study - ITT Population [ Time Frame: Days 1 to 180 ]
    Cumulative incidences of COPD-related deaths until Day 30/60/90/120/150/180 were obtained.

  14. Time to Next Positively Adjudicated Moderate/Severe COPD Exacerbation- ITT Population [ Time Frame: Day 1 to Day 180 ]
    Time to next positively adjudicated moderate/severe COPD exacerbation (in days) was defined as date when first moderate/severe COPD exacerbation symptoms started - date when current COPD exacerbation symptoms stopped, where COPD exacerbations experienced during the study were positively adjudicated by the Independent Adjudication Committee. Time to next positively adjudicated COPD exacerbation was presented in 25th percentile (95% confidence interval) as medians were not evaluable.

  15. Time From Hospitalization Admission Until the Participant Is Medically Ready for Discharge (Current COPD) - ITT Population [ Time Frame: Day 1 to Day 30 ]
    Time from hospitalization admission until the participant is medically ready for discharge (in days) = Date participant was medically ready for discharge from hospital - Date of hospitalization admission. Date of hospitalization admission' and 'Date participant was medically ready for discharge from hospital' were recorded on the 'Current COPD Exacerbation' form of the eCRF. Results were presented with 75th percentile (95% CI) due to the fact that 95% CI for the median was not evaluable.

  16. Percentage of Days With Intake of COPD Rescue Therapy - ITT Population [ Time Frame: Baseline to Week 26 ]
    Participants completed the EXACT-PRO starting from Day 1 and recorded rescue medication use and any occurrences of COPD once a day (evening) in the diary. The percentage of days with intake of rescue medications was evaluated on the basis of the information recorded daily by the participant on the diaries. A day was considered with intake of rescue medications if the answer to the question "How many puffs of rescue medication did you take since last evening?" was> 0.


Other Outcome Measures:
  1. Pharmacokinetic (PK) of BCT197 in Adults With COPD - PK Population [ Time Frame: Days 1 to 5 ]
    Descriptive summary of PK plasma concentration is presented as no-specific PK report is available.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female adults
  • Presence of an active exacerbation of the ongoing COPD requiring hospitalization for treatment
  • Subjects with a documented diagnosis of COPD C or D
  • Current smokers or ex-smokers
  • A documented history of at least one moderate or severe COPD exacerbation in the 12 months preceding the Screening Visit that required antibiotics and/or systemic corticosteroid.
  • Current regular treatment for COPD (for at least 2 months prior to the Screening Visit.

Exclusion Criteria:

  • Age less than 40 years old
  • Current diagnosis of asthma
  • Subjects who have already completed treatment for the current exacerbation of COPD
  • Subjects currently requiring intensive care unit (ICU) and/or mechanical ventilation
  • Received a course of PDE4, p38 or PDE3/4 inhibitors within their respective defined washout periods.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02700919


Locations
Layout table for location information
United States, Indiana
Mereo Research Site
Michigan City, Indiana, United States
United States, Maryland
Mereo Research Site
Baltimore, Maryland, United States
United States, Wisconsin
Mereo Research Site
Milwaukee, Wisconsin, United States
Bulgaria
Mereo Research Site
Dupnitsa, Bulgaria
Mereo Research Site
Gabrovo, Bulgaria
Mereo Research Site
Kardzhali, Bulgaria
Mereo Research Site
Kozloduy, Bulgaria
Mereo Research Site
Kyustendil, Bulgaria
Mereo Research Site
Lovech, Bulgaria
Mereo Research Site
Montana, Bulgaria
Mereo Research Site
Razgrad, Bulgaria
Mereo Research Site
Ruse, Bulgaria
Mereo Research Site
Shumen, Bulgaria
Mereo Research Site
Sliven, Bulgaria
Mereo Research Site
Sofia, Bulgaria
Czechia
Mereo Research Site
Kyjov, Czechia
Mereo Research Site
Melnik, Czechia
Mereo Research Site
Slany, Czechia
Germany
Mereo Research Site
Dresden, Germany
Hungary
Mereo Research Site
Balassagyarmat, Hungary
Mereo Research Site
Budapest, Hungary
Mereo Research Site
Debrecen, Hungary
Mereo Research Site
Farkasgyepu, Hungary
Mereo Research Site
Miskolc, Hungary
Mereo Research Site
Mohacs, Hungary
Italy
Mereo Research Site
Naples, Italy
Latvia
Mereo Research Site
Daugavpils, Latvia
Mereo Research Site
Riga, Latvia
Mereo Research Site
Valmiera, Latvia
Poland
Mereo Research Site
Chrzanow, Poland
Mereo Research Site
Krakow, Poland
Mereo Research Site
Proszowice, Poland
Mereo Research Site
Wroclaw, Poland
Mereo Research Site
Zgierz, Poland
Romania
Mereo Research Site
Bucharest, Romania
Mereo Research Site
Cluj Napoca, Romania
Mereo Research Site
Constanta, Romania
Mereo Research Site
Craiova, Romania
Mereo Research Site
Marghita, Romania
Mereo Research Site
Suceava, Romania
Mereo Research Site
Timisoara, Romania
Russian Federation
Mereo Research Site
Izhevsk, Russian Federation
Mereo Research Site
Kemerovo, Russian Federation
Mereo Research Site
Saint Petersburg, Russian Federation
Mereo Research Site
Saratov, Russian Federation
Mereo Research Site
Tomsk, Russian Federation
Sponsors and Collaborators
Mereo BioPharma
Investigators
Layout table for investigator information
Study Director: Jacqueline Parkin, PhD FRCP Mereo BioPharma
  Study Documents (Full-Text)

Documents provided by Mereo BioPharma:
Study Protocol  [PDF] November 8, 2016
Statistical Analysis Plan  [PDF] November 16, 2017

Layout table for additonal information
Responsible Party: Mereo BioPharma
ClinicalTrials.gov Identifier: NCT02700919    
Other Study ID Numbers: MBCT206
First Posted: March 7, 2016    Key Record Dates
Results First Posted: November 30, 2020
Last Update Posted: November 30, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases